Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC-121 is a synthetic octapeptide somatostatin analog developed for its potential antineoplastic properties. It acts as an agonist at somatostatin receptors, leading to the inhibition of growth hormone and prolactin secretion, and potentially interfering with the action of various growth factors. In experimental models, it has been studied as an adjunct to luteinizing hormone-releasing hormone (LHRH) agonists to enhance the suppression of prostate cancer growth. Structurally, it is closely related to vapreotide (RC-160), differing only by the presence of a C-terminal threonine residue instead of tryptophan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RC-121.